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Abstract: Postmenopausal women are at higher risk of developing cardiovascular diseases due to
changes in lipid profile and body fat, among others. The aim of this study was to evaluate the
association of urinary tartaric acid, a biomarker of wine consumption, with anthropometric (weight,
waist circumference, body mass index (BMI), and waist-to-height ratio), blood pressure, and bio-
chemical variables (blood glucose and lipid profile) that may be affected during the menopausal
transition. This sub-study of the PREDIMED (Prevención con Dieta Mediterránea) trial included a
sample of 230 women aged 60–80 years with high cardiovascular risk at baseline. Urine samples
were diluted and filtered, and tartaric acid was analyzed by liquid chromatography coupled to
electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). Correlations between tartaric
acid and the study variables were adjusted for age, education level, smoking status, physical ac-
tivity, BMI, cholesterol-lowering, antihypertensive, and insulin treatment, total energy intake, and
consumption of fruits, vegetables, and raisins. A strong association was observed between wine
consumption and urinary tartaric acid (0.01 µg/mg (95% confidence interval (CI): 0.01, 0.01), p-value
< 0.001). Total and low-density lipoprotein (LDL) cholesterol were inversely correlated with urinary
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tartaric acid (−3.13 µg/mg (−5.54, −0.71), p-value = 0.016 and −3.03 µg/mg (−5.62, −0.42), p-value
= 0.027, respectively), whereas other biochemical and anthropometric variables were unrelated.
The results suggest that wine consumption may have a positive effect on cardiovascular health in
postmenopausal women, underpinning its nutraceutical properties.
Keywords: PREDIMED; Mediterranean diet; lipid profile; cardiovascular risk; polyphenols; menopause;
body fat; biomarkers; tartaric acid
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide in both sexes.
Nevertheless, important sex-specific differences exist. According to the American Heart
Association, menopause is listed as a female-specific cardiovascular risk factor (CVRF) [1].
During the menopause transition women experience adverse changes in their lipid profile,
body fat distribution, metabolic syndrome risk, and vascular health [2–5]. Previous studies
suggested that menopause is associated with increased total and low-density lipoprotein
(LDL) cholesterol [6] and changes in body composition such as increased fat mass and
loss of lean mass [7]. Changes in blood pressure (BP), waist circumference (WC), body
mass index (BMI), and blood glucose and insulin have not been specifically associated
with menopause and appear to reflect chronological aging [5,6,8]. Therefore, menopause-
induced increases in cholesterol, body fat, and possibly other CVRFs may accelerate the
risk of developing CVD.
Diet and lifestyle can also affect the incidence of CVD. Modifiable factors, such as
smoking cessation, healthy diet, and regular physical activity, play a crucial role in reducing
cardiovascular risk [9]. The Mediterranean diet (MedDiet) has been associated with a
better control of several CVRFs [10] through improvements in BP, lipid profile, glucose
metabolism, arrhythmia risk, and gut microbiome [11,12]. One of the main characteristics
of the MedDiet is the abundant consumption of olive oil, vegetables, fruits, nuts, legumes,
fish, and cereals, and moderate wine consumption [13,14]. Epidemiologic studies and
randomized clinical trials reported that moderate consumption of wine (1 or 2 glasses/day)
during meals has been consistently associated with a lower risk of CVD [15–17]. In
the context of a MedDiet, moderate alcohol consumption appears to be synergistic with
other cardioprotective components of the MedDiet that increase high-density lipoprotein
(HDL) cholesterol, decrease platelet aggregation, promote antioxidant effects, and reduce
inflammation [13].
Wine consumption is mainly determined through dietary questionnaires. A biomarker
of wine intake reflects its consumption more reliably than a questionnaire, since people may
not accurately report the amount of alcohol consumed due to perceived social rejection of
excessive consumption [18]. Tartaric acid, the main organic acid in wine and the molecule
responsible for wine acidity, is present in high amounts in wine (1.5–4.0 g/L) but is rare
in most common foods [19,20]. Urinary tartaric acid has been considered as a sensitive,
selective, and robust biomarker of moderate wine intake [21,22]. Therefore, determining
tartaric acid stands out as a useful tool to further study the impact of moderate wine
drinking on health. The aim of this study was to determine the association between urinary
tartaric acid as a biomarker of wine consumption and CVRFs in postmenopausal women
at risk of developing CVD.
2. Materials and Methods
2.1. Study Design
This study is a cross-sectional analysis of baseline data from a subsample of partic-
ipants in the PREDIMED (PREvención con DIeta MEDiterránea) study, a large, parallel-
group, multicenter, randomized, controlled, 5-year clinical trial conducted between 2003
and 2009. The objective was to assess the effect of a Mediterranean diet supplemented with
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extra-virgin olive oil or mixed nuts as compared to a low-fat diet on the primary prevention
of CVD in 7447 participants at high cardiovascular risk. Eligible participants were men
(55–80 years old) and women (60–80 years old) who had type 2 diabetes mellitus or at least
3 of the following major CVRFs: smoking, hypertension, elevated LDL cholesterol, low
HDL cholesterol, overweight or obesity, and/or family history of premature coronary heart
disease [23]. All participants provided written informed consent, and the study protocol
and procedures complied the ethical standards of the Declaration of Helsinki.
For the present sub-study of the PREDIMED trial, urinary tartaric acid was analyzed in
a subsample of women equivalent to 5% of the total female population of the PREDIMED
study. The 230 women that were randomly selected had undergone the menopausal
transition and their urine samples were available at baseline. Participants who had no
available data of total energy intake or reported extreme values (>3500 kcal/day) were
excluded from the analysis (n = 8).
2.2. Anthropometric, Dietary, and Physical Activity Assessments
Trained personal performed the anthropometric and clinical measurements (height,
weight, WC, and BP). BMI was obtained by dividing the body weight in kilograms by the
square of height in cm. The waist-to-height ratio (WtHR) was calculated by dividing the
WC in centimeters by height in meters. Systolic (SBP) and diastolic blood pressure (DBP)
were measured in triplicate with a validated semi-automatic oscillometer (Omron HEM-
705CP, Lake Forest, IL, USA). A validated semi-quantitative food frequency questionnaire
(FFQ), which included 137 food items [24], and the Minnesota Leisure-Time Physical
Activity Questionnaire [25] were used to assess dietary habits over the previous 12 months
and physical activity (metabolic equivalent tasks per minute per day, METs min/day) of
the participants.
2.3. Clinical Measurements
Medical conditions, family history of disease, and risk factors were collected though
a questionnaire during the first screening visit. Biological samples (plasma and urine)
were collected at baseline after 12 h overnight fast and stored at −80 ◦C until assay. Blood
glucose, total cholesterol, triglycerides, and HDL cholesterol were determined by standard
enzymatic methods, and LDL cholesterol was calculated by the Friedewald equation [26].
2.4. Tartaric Acid Determination
2.4.1. Reagents and Standards
Formic acid (approximately 98%), picric acid (98%, moistened with approximately
33% water), and sodium hydroxide (≥98%) were obtained from Panreac. L-(+)-Tartaric acid
and creatinine were purchased from Sigma. The labelled internal standard DL-(±)-tartaric-
2,3-d2 acid was obtained from C/D/N Isotopes. Solvents were high-performance liquid
chromatography grade, and all other chemicals were analytical reagent grade. Ultrapure
water was obtained from a Milli-Q Gradient water purification system (Millipore, Bedford,
MA, USA).
Stock solutions of tartaric acid were prepared in water. Working standard solutions
that ranged from 0.01 to 5 µg/mL were made by appropriate dilution in 0.5% formic acid
in water and then stored in amber glass vials at −20 ◦C.
2.4.2. Sample Preparation
Determination of urinary tartaric acid was performed following a previously validated
stable-isotope dilution LC-ESI-MS/MS method by our research group [27]. Briefly, urine
samples (20 µL) were diluted 1:50 (v:v) with 0.5% formic acid in water, and 10 µL of a
deuterated isotope standard solution in water (DL-(±)-tartaric-2,3-d2 acid, 200 µg/mL)
were added. The sample dilution was passed through a 0.20 µm filter and analyzed by
LC–ESI-MS/MS. Urinary tartaric acid data were corrected by urine creatinine, measured
according to the adapted Jaffé alkaline picrate method for thermo microtiter 96-well plates,
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according to Medina-Remón et al. [28]. Finally, urinary tartaric acid was expressed as µg of
tartaric acid per mg of creatinine. According to previous data, the cut-off of 8.84 µg/mg
creatinine was used to discriminate daily consumers and non-consumers of wine [21].
2.4.3. LC–ESI-MS/MS Analysis
After filtration, tartaric acid was analyzed using an Atlantis TE C18, 100 mm × 2.1 mm,
3 µm (Waters, Milford, MA, USA) reversed-phase column coupled for detection to the
triple quadrupole mass spectrometer API 3000 (Applied Biosystems, Foster City, CA, USA).
The mass spectrometer was operated in negative electrospray ionization mode. The col-
umn was maintained at 25 ◦C throughout the analysis. Mobile phases A and B were 0.5%
formic acid in water and 0.5% formic acid in acetonitrile, respectively. The following linear
gradient was used: holding at 100%A for 3.5 min, decrease to 10%A over 2 min and holding
for 2 min, return to initial conditions for 1.5 min, and re-equilibration for 6 min. The flow
rate was set at 350 µL/min and the injection volume was 10 µL. Post-column addition of
acetonitrile (250 µL/min) was carried out to improve analyte ionization efficiency. The
detection was accomplished in multiple reaction monitoring (MRM) mode, and the fol-
lowing MS/MS transitions were used for quantification and confirmation, respectively:
m/z 149/87 and m/z 149/73 for tartaric acid, and m/z 151/88 and m/z 151/74 for the
deuterated isotope.
2.5. Statistical Analyses
The baseline characteristics of participants are presented as means and standard
deviations (SD) for continuous variables, and frequency (n) and percentage (%) for categor-
ical variables.
The normality of continuous variables was assessed with the Shapiro–Wilk test. The
variables without normal distribution were transformed into logarithms. Multiple adjusted
linear regression models were used to assess the differences between urinary tartaric acid
and wine consumption as well as anthropometric and biochemical measurements. Three
different adjustment models were applied. Model 1 was minimally adjusted for age (con-
tinuous). Model 2 was additionally adjusted for educational level, smoking status, BMI
(except for anthropometric criteria), physical activity, and cholesterol-lowering, antihy-
pertensive, and insulin treatment. Model 3 was further adjusted for total energy intake
and consumption of fruits, vegetables, and raisins. We used robust variance estimators
to account for the recruitment center in all linear models. To illustrate the relationship
between wine consumption and urinary tartaric acid, the mL per month of wine reported
in the FFQ were transformed into glasses of wine (with 1 glass equivalent to 100 mL).
Values are shown as 95% confidence interval (CI) and significance for all statistical
tests was based on bilateral contrast set at p < 0.05. All the statistical analyses were




The main characteristics of the PREDIMED participants who were included in this sub
study are summarized in Table 1. The mean age of the women was 66.9 + 0.4 years. Their
burden of CVRFs was high: 42.1% had been diagnosed with type 2 diabetes, 87.3% with
hypertension, and 76.5% with hypercholesterolemia. Among the drug treatments, statins
were the most common medication, with 40.72% of them under treatment. Furthermore,
9.1% of the participants were current smokers. Finally, 82% of the participants had a low
educational level.
Up to 45.7% of the participants reported wine consumption in the FFQ. The mean con-
centration of tartaric acid in urine was 28.34 µg/mg creatinine, and 40.4% were considered
daily consumers of wine.
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Table 1. Baseline characteristics of the women in the study population (n = 222).
General Characteristics
Age, years 66.9 ± 0.4
Type 2 diabetes, n (%) 93 (42.08)
Hypertension, n (%) 193 (87.34)
Hypercholesterolemia, n (%) 169 (76.55)
Medication use, n (%)
ACE inhibitors 64 (28.96)
Diuretics 58 (26.24)
Statins 90 (40.72)
Other lipid-lowering agents 14 (6.33)
Insulin 10 (4.52)
Oral hypoglycemic agents 53 (23.98)
Antiplatelet therapy 46 (20.81)
Current smoker, n (%) 20 (9.05)
Leisure-time physical activity, MET·min/week 186.5 ± 10.9




Wine consumption, n (%) 101 (45.70)
Urinary tartaric acid, µg/mg creatinine 28.47 + 4.03
Daily wine consumers, n (%) 81 (40.4)
Anthropometric measurements, mean + SD
Weight, kg 72.9 ± 0.7
BMI, kg/m2 30.3 ± 0.28
WC, cm 97.5 ± 0.7
WtHR 63.0 ± 0.5
Biochemical measurements, mean + SD
Total cholesterol, mg/dL 221.0 ± 2.7
LDL cholesterol, mg/dL 136.5 ± 2.4
HDL cholesterol, mg/dL 57.7 ± 1.0
Triglycerides, mg/dL 134.0 ± 5.2
Glucose, mg/dL 118.1 ± 2.4
Blood pressure, mean + SD
Systolic, mm Hg 148.7 ± 1.2
Diastolic, mm Hg 83.8 ± 0.6
Dietary intake, mean + SD
Total energy, kcal/day 2161 ± 33
Carbohydrate, % of energy 42.0 ± 0.5
Protein, % of energy 16.8 ± 0.2
Fat, % of energy 39.8 ± 0.5
ACE: angiotensin-converting enzyme; MET: metabolic equivalent task; BMI: body mass index; WC: waist circum-
ference; WtHR: waist-to-height ratio; LDL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein
cholesterol. Data are expressed as the mean ± standard deviations (SD) for continuous variables and frequency
(n) and percentage (%) for categorical variables.
The mean values of anthropometric measurements revealed that most participants
were obese, as defined by their BMI, WC, and WtHR data [29] according to the International
Diabetes Federation and the American Heart Association [30]. Regarding biochemical
measurements, triglycerides and HDL cholesterol were at desirables levels, while total
cholesterol, LDL cholesterol and glucose were borderline high [31,32].
The mean energy intake was 2161 kcal/day, of which carbohydrates accounted for
42.0% of the energy consumed, protein intake 16.8%, and fat intake 39.8%.
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3.2. Tartaric Acid as a Biomarker of Wine Consumption
After adjustments for several covariates (age, education level, smoking status, physical
activity, BMI, cholesterol-lowering, antihypertensive, and insulin treatment, total energy
intake, and consumption of fruits, vegetables, and raisins), women who consumed more
wine presented higher concentrations of tartaric acid in urine (0.01 µg/mg (95% CI: 0.01,
0.01), p-value < 0.001). Figure 1 illustrates the linear relationship between urinary tartaric
acid concentrations and wine consumption expressed as glasses of wine, excluding those
who reported not consuming wine.
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Figure 1. Relationship between urinary tartaric acid concentrations in urine and wine consumption
expressed as glasses of wine.
3.3. Anthropometric Measurements and Urinary Tartaric Acid
After adjustment for several covariates, e observed no association between urinary
tartaric acid and BMI, WC, weight, WtHR, and systolic or diastolic BP (Table 2).
Table 2. Association between anthropometric variables and urinary tartaric acid (µg/mg creatinine).
β (95% IC) p-Value
BMI, kg/m2
Model 1 <−0.01 (−0.01, 0.01) 0.519
Model 2 <−0.01 (−0.01, 0.01) 0.426
Model 3 <−0.01 (−0.01, 0.01) 0.973
WC, cm
Model 1 0.56 (−0.25, 1.38) 0.173
Model 2 0.61 (−0.04, 1.26) 0.064
Model 3 0.70 (−0.12, 1.51) 0.087
Weight, kg
Model 1 <−0.01 (−0.01, 0.01) 0.770
Model 2 <−0.01 (−0.01, 0.01) 0.766
Model 3 <0.01 (−0.01, 0.01) 0.886
WtHR
Model 1 0.29 (−0.25, 0.82) 0.291
Model 2 0.32 (−0.17, 0.81) 0.175
Model 3 0.41 (−0.14, 0.96) 0.128
BMI: body mass index; WC: waist circumference; WtHR: waist-to-height ratio; CI: confidence interval. Regression
coefficients (95%CI) were obtained from multivariable adjusted linear regression models. β: Non-standardized
coefficient. Model 1: adjusted for age. Model 2: adjusted for age, educational level, smoking status, physical
activity, and cholesterol-lowering, antihypertensive, and insulin treatment. Model 3: adjusted for age, educational
level, smoking status, physical activity, cholesterol-lowering, antihypertensive, and insulin treatment, total
energy intake, and consumption of fruits, vegetables, and raisins. We used robust standard errors to account for
recruitment center. p-values < 0.05 were considered significant.
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3.4. Biochemical and Clinical Measurements and Urinary Tartaric Acid
A negative association was observed between urine tartaric acid and total and LDL
cholesterol after full adjustment (−3.13 µg/mg (−5.54, −0.71), p-value = 0.016 and −3.03 µg/mg
(−5.62, −0.42), p-value = 0.027, respectively). By contrast, no differences were observed
for HDL with different concentrations of tartaric acid. Finally, no association was found
between triglycerides and glucose and tartaric acid concentrations (Table 3).
Table 3. Association between biochemical variables and blood pressure and urinary tartaric acid
(µg/mg creatinine).
β (95% CI) p-Value
Total cholesterol, mg/dL
Model 1 −3.32 (−6.53, −0.10) 0.043
Model 2 −3.24 (−5.78, −0.72) 0.017
Model 3 −3.13 (−5.54, −0.71) 0.016
LDL cholesterol, mg/dL
Model 1 −3.44 (−6.34, −0.53) 0.021
Model 2 −3.43 (−5.86, −1.00) 0.010
Model 3 −3.03 (−5.62, −0.42) 0.027
HDL cholesterol, mg/dL
Model 1 <−0.01 (−0.02, 0.02) 0.689
Model 2 −0.01 (−0.03, 0.01) 0.220
Model 3 <−0.01 (−0.02, 0.01) 0.633
Triglycerides, mg/dL
Model 1 0.01 (−0.04, 0.05) 0.739
Model 2 0.02 (−0.03, 0.07) 0.422
Model 3 0.02 (−0.04, 0.07) 0.525
Glucose, mg/dL
Model 1 0.02 (<−0.01, 0.04) 0.092
Model 2 0.03 (−0.01, 0.07) 0.119
Model 3 0.02 (−0.01, 0.06) 0.180
Systolic BP, mmHg
Model 1 −0.34 (−1.79, 1.11) 0.647
Model 2 −0.09 (−1.53, 1.71) 0.904
Model 3 0.36 (−1.27, 1.99) 0.633
Diastolic BP, mmHg
Model 1 0.05 (−0.71, 0.81) 0.893
Model 2 0.24 (−0.47, 0.95) 0.472
Model 3 0.21 (−0.47, 0.89) 0.502
BP: blood pressure; LDL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; CI:
confidence interval. Regression coefficients (95%CI) were obtained from multivariable adjusted linear regression
models. β: Non-standardized coefficient. Model 1: adjusted for age. Model 2: adjusted for age, educational level,
smoking status, physical activity, BMI, and cholesterol-lowering, antihypertensive, and insulin treatment. Model
3: adjusted for age, educational level, smoking status, physical activity, cholesterol-lowering, antihypertensive,
and insulin treatment, total energy intake, and consumption of fruits, vegetables, and raisins. We used robust
standard errors to account for recruitment center. p-values < 0.05 were considered significant.
4. Discussion
In this sub-analysis of a subset of postmenopausal women participating in the PRED-
IMED trial, urinary tartaric acid concentrations as an objective biomarker of wine intake
were significantly associated with lower concentrations of total and LDL cholesterol. No
associations with anthropometric variables or blood pressure were observed. To the best
of our knowledge, the current study is the first to evaluate wine consumption based on a
biomarker in a postmenopausal population at increased risk of developing CVD.
Wine consumption has been widely studied due to its beneficial effects on cardio-
vascular and metabolic health [10]. However, most studies have evaluated wine intake
using FFQs or self-questionnaires instead of biological biomarkers, a more reliable and
objective way of assessing dietary habits [33]. It has been previously demonstrated that
urinary tartaric acid is a specific and sensitive biomarker, as its major sources in the diet
are grapes and wine [21,34]. Accordingly, we observed a positive association between
wine consumption reported in the FFQs and the concentrations of tartaric acid present
in urine. Other phenolic compounds, such as resveratrol and its metabolites, have been
proposed as wine biomarkers. However, the resveratrol content in wine is subject to a high
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variability and its metabolism shows interindividual differences [35]. Thus, selectivity and
high correlation with reported intakes make tartaric acid a reliable dietary biomarker of
wine consumption.
Different studies have evaluated how alcohol intake affects different parameters
of body composition. A cross-sectional study in French adults suggested an inverse
association in women of wine intake 100 g/day with BMI and WtHR [36]. Tresserra-
Rimbau et al. analyzed the effects of red wine consumption on the prevalence of metabolic
syndrome and its components, and found a negative association between moderate red
wine consumption and BMI [16]. Tolstrup et al. also described inverse associations between
alcohol consumption and WC in women [37], while other studies found no relationship
between alcohol consumption and body weight in women [38,39]. The mentioned literature
indicates that moderate consumption of wine, an alcoholic beverage that contributes to
energy intake, is not related to weight gain or detrimental changes in body composition.
Our study supports this notion, as we did not observe any differences in BMI, weight, WC,
and WtHR with increasing wine consumption.
Evaluating the effect of alcohol, and specifically wine, on the risk of developing
CVD in women is important due to the increase in cardiovascular risk after menopause.
Among CVRFs, a recent metanalysis reported that triglycerides, total cholesterol, LDL
cholesterol, and the total cholesterol-to-HDL-cholesterol ratio were significantly higher
in postmenopausal women compared to premenopausal women, and suggested that age
was partly responsible for the differences in lipid levels [40]. We found that women
with higher concentrations of tartaric acid presented lower total and LDL cholesterol.
Similarly to our results, Rifler et al. reported that after 2 weeks of drinking 250 mL of
red wine daily, patients post myocardial infarction presented a 5% decrease in total and
LDL cholesterol [41]. Furthermore, Taborsky et al. evaluated the effect of 1 year of wine
consumption, and observed a reduction in total and LDL cholesterol [42]. In another clinical
trial, authors reported a similar beneficial effect on the lipid profile after consumption
of red wine in asymptomatic hypercholesterolemic individuals [43]. The data are almost
consistent in showing that wine consumption reduces LDL cholesterol while increasing
HDL cholesterol [44,45]. Moderate consumption of alcohol has been associated with higher
concentrations of HDL cholesterol and diminished lipid oxidation stress [46]. Resveratrol
metabolites in urine, as biomarkers of wine consumption, were significantly associated with
lower triglycerides and higher HDL-cholesterol [47]. However, we were unable to confirm
that higher urinary tartaric acid as a biomarker of wine consumption was associated with
raised HDL cholesterol levels. A probable reason is that the women studied had rather
high baseline HDL cholesterol levels, making it more difficult to further increase these
with interventions.
Many clinical studies support that light to moderate alcohol consumption, in par-
ticular of red wine, is associated with lower CVD rates and an improved lipid profile
and inflammatory system [17,48]. However, it remains unknown whether this effect of
wine is due to alcohol per se, the phytochemicals of wine, their combined effect, or even
the time of drinking, since postprandial oxidative stress after a meal appears to be coun-
teracted by the ingestion of red wine [49]. In this sense, it has been found that wine
micro-constituents modulate inflammatory mediators and therefore may be responsible
for attenuating postprandial inflammation [50]. In addition, they protect against the effect
of ethanol on cytokine secretion, which are involved in inflammatory processes [51]. In
support of this view, a randomized clinical trial reported that wine bioactive compounds,
such as resveratrol, can decrease total cholesterol by reducing mRNA expression of hepatic
3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, in addition to the increased
activation of the sirtuin system in all tissues [52]. Experimental work in cell cultures and
animal models has shown that the enhancement of Sirtuin 1 can lead to better metabolic
profiles and anti-inflammatory activities, as well as increased reverse cholesterol trans-
port [53]. Overall, evidence supports that wine micro-constituents play a crucial role in the
protective effect of wine on cardiovascular health by exerting anti-inflammatory actions.
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The main strength of this study is that it used a biological biomarker, tartaric acid, to
evaluate wine consumption, instead of less reliable methods such as FFQs or self-reported
questionnaires. Moreover, it involved baseline data of participants in the PREDIMED trial;
therefore, the results reflect real-life conditions. The main limitations were the modest
sample size and the impossibility of determining causality due to the cross-sectional design.
5. Conclusions
The findings from the current cross-sectional study support the notion that wine
intake has beneficial nutraceutical effects on the cardiovascular health of postmenopausal
women, as its biomarker tartaric acid was associated with lower total and LDL cholesterol
concentrations. Randomized trials are needed to confirm these results and determine the
impact of wine consumption on cardiovascular health in a sensitive population such as
that of postmenopausal women.
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